Revalidation of the ATTRACTION-4 study in a real-world setting: a multicenter, retrospective propensity score matching study in China
Open Access
- 15 September 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1264929
Abstract
Background: Immune-checkpoint inhibitors (ICIs) combined with chemotherapy have been successfully used in clinical trials to treat advanced gastric cancer. However, the efficacy and safety of first-line immunotherapy combined with chemotherapy in Chinese patients are unknown.Methods: This multicenter retrospective study included patients with human epidermal growth factor receptor-2 (HER-2) negative advanced gastric cancer treated with first-line chemotherapy or chemotherapy with an ICI between January 2019 and December 2022. Propensity score matching was used to compare progression-free survival (PFS), overall survival, objective response rates, and adverse reactions between cohorts.Results: After propensity score matching, 138 patients, who had balanced baseline characteristics, were included in the chemotherapy and combination treatment groups. The median follow-up duration was 16.90 months, and the median PFS was 8.53 months (95% confidence interval [CI] 7.77-9.28) in the combination treatment group and 5.97 months (95% CI 4.56-7.37) in the chemotherapy group. The median survival duration was 17.05 months (95% CI 14.18-19.92) in the combination treatment group and 16.46 months (95% CI 12.99-19.93) in the chemotherapy group. The PFS subgroup analysis revealed that age ≥65 years, women, Eastern Cooperative Oncology Group performance status of 1, non-signet ring cell carcinoma, esophagogastric junction, liver metastasis, peritoneal metastasis, no massive ascites, only one metastatic organ, and combined platinum-based chemotherapy correlated with treatment benefit. The incidences of adverse events above grade 3 were comparable between groups.Conclusions: Our study confirmed the ATTRACTION-4 trial results. Compared with chemotherapy, first-line ICIs combined with chemotherapy prolonged PFS but did not improve overall survival in patients with HER-2-negative advanced gastric cancer.Keywords
This publication has 31 references indexed in Scilit:
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance studyThe Lancet Oncology, 2018
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent MannerCancer Research, 2018
- Myocarditis in Patients Treated With Immune Checkpoint InhibitorsJACC, 2018
- Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancerOncology Reports, 2017
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapyClinical Immunology, 2008
- Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouseCancer Immunology, Immunotherapy, 2008
- Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin productionCancer Immunology, Immunotherapy, 2004